Sêmeia has raised €21 million to expand its remote patient monitoring footprint and accelerate its external growth strategy

Having achieved profitability and large-scale deployment of remote monitoring in nephrology, Sêmeiais now strengthening its capabilities to:

1. expand its offering to healthcare professionalsby addressing new pathologies and delivering innovative services for both careand clinical research;

2. pursue its external growth strategy following two successful acquisitions.

“This funding round opens a new chapter in Sêmeia’s journey. It strengthens our teams’ ability to support healthcare professionals and patients. We are also delighted to welcome new partners who are fully aligned with our ambition to generate a concrete and lasting impact on the healthcare system.”--Pierre Hornus, CEO of Sêmeia.

‍

A LEADING SOLUTION FOR REMOTE MONITORING WITH PROVENOUTCOMES

The growing prevalence of chronic diseases, which is expected to affect up to 16 million patients and account for 75% of the health budget in France alone by 2035, coupled with the ongoing shortage of healthcare professionals, challenges the entire health system. Remote patient monitoring is now recognized as a key driver to optimize care pathways, benefiting health professionals, patients, and the overall efficiency of the healthcare system.

With over 35,000 patients monitored across 500 healthcare facilities, the Toulouse-based company is the leading French solution for multi-pathology remote monitoring.

Its data-driven medical device, MedicWise, is already active in the fields of nephrology, transplantation, mental health, and cardiology, providing practitioners with automatic collection, structuring, and display of outpatient data as well as the generation of highly targeted alerts.

In nephrology, where Sêmeia is the go-to solution, remote patient monitoring has proven to offer both clinical and organisational benefits: a 26% reduction in patients’ hospitalis ations and a 73% reduction in physicians’ time¹.

Almost a third of patients followed up by Sêmeia live in areas with limited access to healthcare, demonstrating its active contribution to reducing regional disparities in access to care.

‍

SETTING A NEW CHAPTER: SETTLE MULTI-PATHOLOGY TELEMEDICINE AS A STANDARD FOR HEALTH PROFESSIONALS AND PATIENTS

Sêmeia is now focusing on the large-scale roll-out of remote patient monitoring products across multiple pathologies, such as mental health conditions like bipolar disorder and depression, type 2 diabetes, IBD, or chronic liver diseases.  

The first medical studies have already revealed significant improvements when using MedicWise, such as a 50% reduction insuicide attempts and a 41% reduction in emergency hospitalisations of patients with bipolar disorder.

‍

AN AMBITION TO SCALE UP TELEMONITORING AND CONSOLIDATE THE EUROPEAN E-HEALTH MARKET

With this new funding, Sêmeia aims to intensify its position as a leader within the European healthcare system.

Support the successful rollout of telemonitoring for new pathologies.

Semeia is planning to drive new medical studies with the support of clinical experts to validate the positive impact of telemonitoring in new pathologies ahead of its market entry. Some are already underway (e.g., in gastroenterology), with more to follow.  

Strengthen investments in data-driven innovation through AI technologies for care and research. 

Semeia is committed to integrating new AI-driven features to enhance software performance continuously and optimise the organisation of medical follow-up. This effort will also support the company’s contribution to over fifteen medical research projects conducted in partnership with clinical teams.

Confirm its position as a key player in the telemedicine market through partnerships and targeted acquisitions.

Sêmeia will pursue a strategy of partnerships and selective acquisitions to improve user experience and the integration of digital solutions into care pathways. After two strategic acquisitions – Optim’ Care in 2022 and Healabs in 2025 – several new discussions are already in progress.

COMMITTED INVESTORS SUPPORTING HIGH-IMPACT MEDICAL INNOVATION

This fundraising brings together investors who are recognised for their commitment to technological innovation and impact-driven companies. These include the German fund Acton Capital, and French impact investment funds, Mutuelles Impact (a fund initiated by Mutualité Française and managed by XAnge in partnership with Impactivist), and Citizen Capital. Historical investors, Banque des Territoires (Groupe Caisse des Dépôts) – for which the operation fully aligns with the implementation of the "Santé et Grand âge" roadmap of the Caissettto des Dépôts Group, committing €25 billion over a 5-year period - and Orange Ventures, have also renewed their commitment alongside Sêmeia.

“We are very happy to take an active part in the support of Sêmeia’s technical expertise and in its ambition to deliver high-impact digital health services. By leveraging innovative technologies, Sêmeiais supporting healthcare professionals and patients for better care while contributing to the efficiency and sustainability of the healthcare system.”--Sebastian Wossagk, Managing Partner, Acton Capital.

‍

About Sêmeia

Foundedin 2017 in Toulouse, Sêmeia offers MedicWise, a platform for the automaticcollection and processing of health data, providing an innovative approach to patient follow-up: both in consultation and remotely, without overburdening patients or care teams. Designed in collaboration with healthcareprofessionals, it combines medical expertise and data science to optimise carepathways, benefiting clinicians, patients, healthcare facilities and the healthsystem as a whole. Our purpose? To help healthcare professionals moreeffectively support their patients living with chronic conditions.

About Acton Capital

Acton Capital is an international venture capital firm located in Munich and Vancouver. Since 1999, the team has invested in technology-based business models from Europe and North America. With over two decades of experience and a deep understanding of digital transformation, Acton Capital has already supported over 100 startups in building successful businesses. In the healthtech space, Acton has backed companies like Hublo (France, exited 2025), Maple (Canada), and Eolas Medical (UK), driving innovation in healthcare HR, telemedicine, and clinical knowledge infrastructure.

‍

‍

¹ Christophe Mariat, Miriana Dinic, Damien Thibaudin, Nicolas Maillard, #2096 A randomized controlled study of telemonitoring in kidney transplantation: interim resultsof the Ap'TX trial, Nephrology Dialysis Transplantation, Volume 39, Issue Supplement_1, May2024, gfae069–0092–2096, https://doi.org/10.1093/ndt/gfae069.092